Crispr Therapeutics shares tumble after significant earnings miss
Michael Cannon-Brookes, CEO and Co-Founder of Atlassian Corp (NASDAQ:TEAM), recently sold shares of the company’s Class A common stock valued at approximately $1.8 million. The transactions, executed on March 12, 2025, involved multiple sales at prices ranging from $225.15 to $232.48 per share. The sales come amid a challenging period for the $54.5 billion market cap company, which has seen its stock decline nearly 10% in the past week.
The sales were carried out under a Rule 10b5-1 trading plan, which Cannon-Brookes adopted in February 2024. Following these transactions, Cannon-Brookes holds 103,324 shares indirectly through a trust. Despite recent market volatility, Atlassian maintains impressive gross profit margins of 82% and receives a FAIR financial health rating from InvestingPro, which offers 12 additional investment tips and comprehensive analysis for the company.
These sales come as part of a series of planned transactions and reflect the ongoing management of Cannon-Brookes’ investment in Atlassian. The shares were sold across multiple trades, with each transaction executed at varying prices within the specified range. While the stock has experienced recent pressure, it has demonstrated strong momentum with a 38% gain over the past six months, according to InvestingPro data.
In other recent news, Atlassian Corp Plc reported strong financial results for Q4 2024, significantly exceeding expectations. The company reported earnings per share of $0.96, surpassing the forecasted $0.62, and revenue of $1.29 billion, which was above the anticipated $1.23 billion. Atlassian’s subscription revenue also saw a 30% year-over-year growth, contributing to its robust financial performance. The company has set an ambitious goal to double its revenue to $10 billion by FY 2026, while maintaining non-GAAP operating margins above 25%.
In terms of market activity, Atlassian has been actively expanding its enterprise market presence, securing a record number of deals over $1 million in annual contract value. The firm also highlighted its progress in AI innovations, which is driving increased adoption of its premium and enterprise editions, with sales up over 40% year over year. Analyst feedback has been positive, with the company’s strategic investments in AI and enterprise go-to-market strategies being noted as key growth drivers.
While Atlassian’s outlook remains optimistic, the company acknowledges macroeconomic uncertainties and competition in the AI and collaborative tools market as potential challenges. The firm continues to invest in enhancing its cloud infrastructure and optimizing costs, aiming to maintain its competitive edge in the industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.